Equities

Cynata Therapeutics Ltd

Cynata Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.21
  • Today's Change0.02 / 10.53%
  • Shares traded303.34k
  • 1 Year change+50.00%
  • Beta0.8265
Data delayed at least 20 minutes, as of Sep 20 2024 02:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Cynata Therapeutics Ltd grew revenues 18.38% from 352.87k to 417.71k while net income improved from a loss of 14.28m to a smaller loss of 9.74m.
Gross margin--
Net profit margin-2,332.89%
Operating margin-2,349.11%
Return on assets-71.18%
Return on equity-81.37%
Return on investment-81.37%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Cynata Therapeutics Ltd fell by 9.96m. Cash Flow from Financing was even, which indicates that this company's capital needs are balanced. In addition the company used 9.96m for operations while cash used for investing totalled .
Cash flow per share-0.0527
Price/Cash flow per share--
Book value per share0.0402
Tangible book value per share0.0299
More ▼

Balance sheet in AUDView more

Cynata Therapeutics Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio5.58
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.